ARGX
argenx SE
$867.69
▲ 2.5%Updated Today 12:18 PM ET
ARGX at a glance — five pillars scored 0–100 from real filed financials.
Overall: Strong · 88/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 70.5% over the last 12 months
Market Cap
$55.53B
P/E
25.98x
Forward P/E (est.)
18.56x
ROE
22.9%
Revenue Growth
80.6%
EPS Growth
111.4%
Profit Margin
48.2%
FCF Yield
—
Debt / Equity
0.01x
ROIC
11.0%
Interest Coverage
258.16x
Current Ratio
5.23x
Dividend Yield
—
Implied Growth (rev. DCF)
7.7%
Rating Score
88/100
argenx SE (ARGX) is a large-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $55.53B.
In its latest reported year it generated about $4.15B in revenue and $1.29B in net profit.
Our model rates ARGX Strong (88/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what ARGX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. ARGX trades near $867.69, above its 50-day average ($838.91) and 200-day average ($818.62). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 56 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. ARGX's is $35.02 (~4.0% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month ARGX found buyers near $837.74 (support) and sellers near $953.58 (resistance); its 52-week range is $536.02–$953.58. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.3× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
3Y CAGR
118.0%
Revenue moved from $400.72M in 2022 to $4.15B in 2025, a 118.0% compound annual growth rate. The most recent year grew a strong 80.6% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
144.5%
Operating Margin
25.4%
Net Margin
31.1%
ROE
22.9%
argenx SE keeps about 48.2% of each sales dollar as net profit, with a 144.5% gross margin and 25.4% operating margin. Return on equity is 22.9% and return on invested capital about 11.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$11.00M
Net Debt
-$3.48B
Net cash position
Net Debt / EBITDA
-3.3x
Debt / Equity
0.01x
Leverage: debt-to-equity is 0.0x, and operating profit covers interest about 258.2x, with a current ratio of 5.2x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $11.00M of total debt against $3.49B of cash.
Operating CF
$685.19M
Free Cash Flow
$679.03M
FCF Margin
16.4%
In the latest year argenx SE produced about $685.19M of operating cash flow and $679.03M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
25.98x
P/S
14.07x
P/B
6.86x
EV / EBITDA
—
ARGX trades at 26.0x trailing earnings (about 18.6x on estimated forward earnings), 14.1x sales, and 6.9x book value. Reverse-engineering today's price implies the market expects roughly 7.7% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$454.39
Current price
$867.69
Starting FCF (latest 10-K)
$679.03M
Growth, years 1–5
20.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where ARGX sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How ARGX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), ARGX ranks #1 of 324 by our overall rating. It trades at roughly in line versus the sector on earnings (26x P/E vs. 25.4x median) with a higher return on equity (22.9% vs. 14.1%) and faster revenue growth (80.6% vs. 7.6%).
P/E vs sector
26x
median 25.4x
ROE vs sector
22.9%
median 14.1%
Growth vs sector
80.6%
median 7.6%
Sector rank
#1
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $867.69 today · expected CAGR 19% – 31%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $6.02B | $8.73B | $12.66B | $18.35B | $26.61B |
| Net income | $1.87B | $2.71B | $3.92B | $5.69B | $8.25B |
| EPS | $29.16 | $42.28 | $61.31 | $88.90 | $128.90 |
| Share price (low) | $466.56 | $676.51 | $980.94 | $1,422.36 | $2,062.42 |
| Share price (high) | $758.16 | $1,099.33 | $1,594.02 | $2,311.34 | $3,351.44 |
| CAGR (low–high) | -46% / -13% | -12% / 13% | 4% / 22% | 13% / 28% | 19% / 31% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for ARGX:
- Revenue is growing 80.6% a year, a sign of real demand.
- High net margins (48.2%) point to pricing power or efficiency.
- Strong return on equity (22.9%) shows capital is put to work well.
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
- Our model's overall read is Strong (88/100).
The case against ARGX:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: argenx SE is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 26.0x earnings, which our model scores Strong (88/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 25 Wall Street analysts covering ARGX recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
ARGX's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
ARGX — frequently asked questions
Is ARGX a good stock to buy?
We don't give buy or sell advice. Our model rates argenx SE Strong (88/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is ARGX's rating on The Stocks School?
argenx SE currently scores 88/100 (Strong) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does ARGX's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from argenx SE's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for ARGX calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this ARGX analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell ARGX. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.